Publication Name	World Journal of Stem Cells
Manuscript ID	56477
Country	United States

Received	2020-05-01 20:41
Peer-Review Started	2020-05-01 20:42
To Make the First Decision
Return for Revision	2020-05-15 06:55
Revised	2020-05-17 07:08
Second Decision	2020-05-21 12:03
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2020-05-22 05:04
Articles in Press	2020-05-22 05:04
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2020-06-18 09:38
Publish the Manuscript Online	2020-06-25 10:09

ISSN	1948-0210 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Respiratory System
Manuscript Type	Minireviews
Article Title	Stem cell therapy for COVID-19 and other respiratory diseases: Global trends of clinical trials
Manuscript Source	Invited Manuscript
All Author List	Hong-Long Ji, Cong Liu and Run-zhen Zhao
ORCID	Author(s) ORCID Number Hong-Long Ji http://orcid.org/0000000232287144 Cong Liu http://orcid.org/0000-0001-6859-4173 Run-zhen Zhao http://orcid.org/0000-0003-4537-6020
Funding Agency and Grant Number	Funding Agency Grant Number NIH HL87017
Corresponding Author	Hong-Long Ji, MD, PhD, Director, Director, Professor, Department of Cellular and Molecular Biology, Texas Lung Injury Institute, University of Texas Health Science Center at Tyler, 11937 U.S. Highway 271, Tyler, TX 75708, United States. james.ji@uthct.edu
Key Words	Pulmonary diseases; COVID-19; Cell therapy; Exosomes; Clinical trial;
Core Tip	Preclinical studies demonstrate significant improvement of lung disorders by stem cells and extracellular vesicles. Completed clinical trials show cell-based therapies are safe and tolerant for acute and chronic respiratory diseases. Current challenges for cell therapy of pulmonary illnesses are long-term safety, efficacy, and personal medicines.
Publish Date	2020-06-25 10:09
Citation	Ji HL, Liu C, Zhao RZ. Stem cell therapy for COVID-19 and other respiratory diseases: Global trends of clinical trials. World J Stem Cells 2020; 12(6): 471-480
URL	https://www.wjgnet.com/1948-0210/full/v12/i6/471.htm
DOI	https://dx.doi.org/10.4252/wjsc.v12.i6.471

Full Article (PDF)	WJSC-12-471.pdf
Full Article (Word)	WJSC-12-471.docx
Manuscript File	56477-Review.doc
Answering Reviewers	56477-Answering reviewers.pdf
Audio Core Tip	56477-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	56477-Conflict-of-interest statement.pdf
Copyright License Agreement	56477-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	56477-Grant application form(s).PDF
Supplementary Material	56477-Supplementary material.xls
Peer-review Report	56477-Peer-review(s).pdf
Scientific Misconduct Check	56477-Scientific misconduct check.pdf
Scientific Editor Work List	56477-Scientific editor work list.pdf
CrossCheck Report	56477-CrossCheck report.pdf